XSHE002258
Market cap862mUSD
Jan 10, Last price
7.90CNY
1D
-1.99%
1Q
-1.86%
Jan 2017
-11.04%
IPO
22.67%
Name
Lier Chemical Co Ltd
Chart & Performance
Profile
Lier Chemical Co.,LTD. engages in the research and development, production, and sale of agrochemical products in the People's Republic of China and internationally. The company offers low-toxicity and low-residue safe pesticides, such as chloropyridines and organophosphates. It also provides herbicides, including pinoxaden, glufosinate-ammonium, diquat, flumioxazin, clodinafop-propargyl, clopyralid acid, picloram, fluroxypyr-meptyl, triclopyr, diuron, bensulfuron-methyl, linuron, pyrazosulfuron-ethyl, nicosulfuron, flufenacet, mefenacet, and quinclorac; fungicides, such as azoxystrobin, epoxiconazole, iprodione, and difenoconazole; and insecticides comprising chlorpyrifos and pyriproxyfen, as well as active pharmaceutical ingredients and preparations. In addition, the company offers chemical intermediates, including 2-chloropyridine; 2,3-dichloropyridine; 2,5-dichloropyridine; 2,6-dichloropyridine; 2,3,4-trichloropyridine; 2,3,5-trichloropyridine; 2,3,6-trichloropyridine; nitrapyrin; pentafluoropyridine; 2,3,5,6-tetrachloro-4-methylsulfonylpyridine; 6-chloropyridine-2-carbonitrile; 3,6-difluoropyridine-2-carboxylic acid; 2,2'-bipyridine; 2-chloro-4'-fluoroacetophenone; 2-chloro-2',4'-difluoroacetophenone; and 2-fluoro-3-nitrobenzoic acid. Further, its intermediates comprise (E)-4-(dimethylamino)but-2-enoic acid hydrochloride; 4,4'-dichloro-[3,3']bipyridinyl; clopyralid-methyl; methyl 3,4,6-trichloropicolinate; 2,4,5-trichloropyridine; 7-fluoro-6-nitro-4-hydroxyquinazoline; N-(3-chloro-4-fluorophenyl)-7-fluoro-6-nitroquinazolin-4-amine; 4-bromocrotonic acid; 4-N-(3-chloro-4-fluorophenyl)-7-[(3S)-oxolan-3-yl]oxyquinazoline-4,6-diamine; 2-amino-N-(2-chloro-6-methylphenyl)-1,3-thiazole-5-carboxamide; and 5-chloro-8-hydroxyquinoline. Lier Chemical Co.,LTD. was founded in 1993 and is headquartered in Mianyang, the People's Republic of China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 7,850,607 -22.55% | 10,136,144 56.08% | |||||||
Cost of revenue | 6,656,168 | 7,481,206 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 1,194,440 | 2,654,938 | |||||||
NOPBT Margin | 15.21% | 26.19% | |||||||
Operating Taxes | 109,917 | 341,885 | |||||||
Tax Rate | 9.20% | 12.88% | |||||||
NOPAT | 1,084,523 | 2,313,053 | |||||||
Net income | 603,888 -66.68% | 1,812,519 69.02% | |||||||
Dividends | (442,669) | (264,272) | |||||||
Dividend yield | 4.62% | 1.84% | |||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
Debt | |||||||||
Debt current | 240,110 | 603,312 | |||||||
Long-term debt | 2,097,210 | 581,848 | |||||||
Deferred revenue | 265,122 | 207,584 | |||||||
Other long-term liabilities | 28,091 | 58,334 | |||||||
Net debt | 872,503 | (223,905) | |||||||
Cash flow | |||||||||
Cash from operating activities | 938,573 | 2,596,557 | |||||||
CAPEX | (1,972,110) | ||||||||
Cash from investing activities | (1,918,346) | ||||||||
Cash from financing activities | 1,018,278 | ||||||||
FCF | (589,509) | 1,178,174 | |||||||
Balance | |||||||||
Cash | 1,464,760 | 1,409,069 | |||||||
Long term investments | 57 | (4) | |||||||
Excess cash | 1,072,286 | 902,258 | |||||||
Stockholders' equity | 7,240,371 | 6,872,778 | |||||||
Invested Capital | 10,297,712 | 8,792,436 | |||||||
ROIC | 11.36% | 29.52% | |||||||
ROCE | 10.43% | 27.25% | |||||||
EV | |||||||||
Common stock shares outstanding | 800,488 | 800,437 | |||||||
Price | 11.97 -33.35% | 17.96 -25.45% | |||||||
Market cap | 9,581,843 -33.35% | 14,375,853 -22.61% | |||||||
EV | 11,709,609 | 15,265,289 | |||||||
EBITDA | 1,823,877 | 3,220,482 | |||||||
EV/EBITDA | 6.42 | 4.74 | |||||||
Interest | 52,236 | 65,965 | |||||||
Interest/NOPBT | 4.37% | 2.48% |